Sterne Kesster

Goldstein Fox

Aug 1 6 2004 Rose

Goldstein Fox

Attorneys at Law

Robart Greene Sterne Edward I. Kessler Jogo A. Goldstein Bavik K.S. Cornwell Sobert W. Esmond fracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Donald J. Featherstone Lawrence B. Bugaisky Michael V. Messinger Judith U. Kim Timothy J. Shea, Ir. Patrick E. Garrett Heidi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes

Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich* George S. Bardmesser Daniel A. Klein* Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* LuAnne M. DeSantis John J. Figueroa Ann E. Summerfield Tiera S. Coston Aric W. Ledford* Jessica L. Parezo Timothy A. Doyle* Gaby L. Longsworth* Nicole D. Dretar* Ted J. Ebersole Jyoti C. Iyer* Laura A. Vogel

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Matthew J. Dowd
Aaron L. Schwartz
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland * Admitted only in Virginia •Practice Limited to Federal Agencies

August 16, 2004

WRITER'S DIRECT NUMBER: (202) 772-8560 INTERNET ADDRESS: RESMOND@SKGF.COM

Art Unit 1636

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/814,634; Filed: April 1, 2004

or: Assay for Identifying Compounds Which Affect Stability of mRNA

Inventors:

KASTELIC et al.

Our Ref:

1556.0290001/RWE/JKM

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Executed Power of Attorney from Assignee with Delegation;
- 2. Executed Statement Under 37 C.F.R. 3.73(b) with attached copies of Notices of Recordation exemplifying the chain of title (4 pgs.); and
- 3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents August 16, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants Registration No. 32,893

RWE/JKM/nef Enclosures

299382_1.DOC

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

Novation Pharmaceuticals Inc., a corporation of Canada, having a principal place of business at 635 Columbia Street, New Westminster, British Columbia, V3M 1A7 CANADA, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on Following Compounds Which Affect Stability of mRNA (Attorney Docket No.1556.0290001/RWE/JKM), that is disclosed and claimed in a patent application of the same title by the inventors Tania KASTELIC and Dominique CHENEVAL (said application filed: HEREWITH at the U.S. Patent and Trademark Office, having Application Number: To Be Assigned).

Gen. No. 32,893

For the purpose of PAIR, the Customer Number is 26111.

The Assignee hereby appoint the U.S. attorneys associated with CUSTOMER NUMBER 28393 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michael A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 37,575; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick E. Garrett, Esq., Registration No. 39,987. The Assignees hereby grant said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from MBM & Co., 270 Albert Street, 14th Floor, Ottawa, Ontario K1P 5GB, Canada as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

Customer Number 26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Novation Pharmaceuticals Inc.
SIGNATURE:
BY: DOMINIOUE CHEVELAC
TITLE: PREMIENT COO
DATE: 4(26(04

PTO/SB/96 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATI	EMENT UNDER 37 CFR 3.73(b) 1556.0290001/RWE/JKM
Applicant/Patent Owner: Tania KASTELIC and	Dominique CHENEVAL
Application No./Patent No.:To Be Assigned	Filed/Issue Date: <u>HEREWITH</u>
Entitled: Assay For Identifying Compounds Wh	ich Affect Stability Of mRNA
Novation Pharmaceuticals Inc(Name of Assignee)	, a <u>Corporation</u> (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. ☑ the assignee of the entire right, title, and in	terest; or
2. an assignee of less than the entire right, tit The extent (by percentage) of its ownership identified above by virtue of either:	le and interest. p interest is% in the patent application patent
A. [x] An assignment from the inventor(s) of the p was recorded in the Patent and Trademark a copy thereof is attached.	patent application/patent identified above. The assignment Office at Reel, Frame, or for which
OR	
B. [] A chain of title from the inventor(s), of the p assignee as shown below:	atent application/patent identified above, to the current
The document was recorded in the	he Patent and Trademark Office at , or for which a copy thereof is attached.
2. From:	To:
The document was recorded in the	he Patent and Trademark Office at, or for which a copy thereof is attached.
From: The document was recorded in the	To:
The document was recorded in the Reel, Frame _	e Patent and Trademark Office at, or for which a copy thereof is attached.
[] Additional documents in the chain of	f title are listed on a supplemental sheet.
	signment document or a true copy of the original document) accordance with 37 CFR Part 3, if the assignment is to be
The undersigned (whose title is supplied below) is	s authorized to act on behalf of the assignee.
4/26/04	DOMINIQUE CHENEVER
Date Co. T. C.	Typed or printed name
(604) 39.5-70GD	- Carel
Telephone number	Signature
	PREMISET (CCO

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231



AUGUST 10, 2004

PTAS

STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005-3934

DO NOT FORWARD TO ASSIGNMENT BRANCH

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/10/2004

REEL/FRAME: 014969/0523

NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

KASTELIC, TANIA

DOC DATE: 12/22/1998

ASSIGNOR:

CHENEVAL, DOMINIQUE

DOC DATE: 12/22/1998

ASSIGNEE:

NOVARTIS AG

PATENT NUMBER:

LICHSTRASSE 35, BLDG. 200-322 BASLE, SWITZERLAND CH-4002

SERIAL NUMBER: 10814634

FILING DATE: 04/01/2004

ISSUE DATE:

TITLE: ASSAY FOR IDENTIFYING COMPOUNDS WHICH AFFECT STABILITY OF MRNA

014969/0523 PAGE 2

REGINA COATES-WHITE, SUPERVISOR ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

AUGUST 10, 2004



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231



PTAS

STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005-3934

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/10/2004

REEL/FRAME: 014969/0520

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

NOVARTIS AG

DOC DATE: 12/21/1999

ASSIGNEE:

NOVATION PHARMACEUTICALS, INC. 1323 REGAN AVENUE COQUITLAM, BRITISH COLUMBIA, CANADA

V3J 3B6

PATENT NUMBER:

SERIAL NUMBER: 10814634

FILING DATE: 04/01/2004

ISSUE DATE:

TITLE: ASSAY FOR IDENTIFYING COMPOUNDS WHICH AFFECT STABILITY OF MRNA

014969/0520 PAGE 2

LAZENA MARTIN, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS